Taysha Gene Therapies Total Current Assets 2020-2024 | TSHA
Taysha Gene Therapies total current assets from 2020 to 2024. Total current assets can be defined as the sum of all assets that are classified as current because they will provide a benefit within one year.
Taysha Gene Therapies Annual Total Current Assets
(Millions of US $) |
| 2023 |
$150 |
| 2022 |
$96 |
| 2021 |
$160 |
| 2020 |
$258 |
| 2019 |
$0 |
Taysha Gene Therapies Quarterly Total Current Assets
(Millions of US $) |
| 2024-06-30 |
$178 |
| 2024-03-31 |
$131 |
| 2023-12-31 |
$150 |
| 2023-09-30 |
$172 |
| 2023-06-30 |
$54 |
| 2023-03-31 |
$72 |
| 2022-12-31 |
$96 |
| 2022-09-30 |
$43 |
| 2022-06-30 |
$77 |
| 2022-03-31 |
$107 |
| 2021-12-31 |
$160 |
| 2021-09-30 |
$197 |
| 2021-06-30 |
$207 |
| 2021-03-31 |
$240 |
| 2020-12-31 |
$258 |
| 2020-09-30 |
$279 |
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.334B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
